Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...

Despite advances, there remain gaps in the understanding of and personalized treatment for chronic pain in rheumatology, especially among women.

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an ...

The following is a summary of “Global Delphi consensus on treatment goals for generalised pustular psoriasis,” published in the January 2025 issue of Dermatology by Barker et al. Generalized pustular ...

The technology was announced at the JP Morgan Healthcare Conference in San Francisco. In this project, the stakeholders aim to use a human reference genome to combine with patient data in order to try ...

Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA). Different parts of the immune system have been targeted by monoclonal ...

Previous GWAS examining the response to biologics (mainly anti-TNF therapy) provided unsatisfactory evidence,63–67 which may suggest that genetic background of RA onset and that of clinical response ...

JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...

The main goal of diabetes treatment is to keep your blood sugar levels in target range. To help monitor them, your doctor will order blood work on a regular basis, including an A1C test.

Cushing syndrome presents with a wide array of symptoms, many of which result from prolonged exposure to elevated cortisol ...

After breaking the 800-goal barrier during the 2022-23 season, Washington Capitals star Alex Ovechkin now has his sights set on breaking Wayne Gretzky's NHL career goals record of 894. Ovechkin ...